Severe thrombocytopenia associated with once-daily rifampin therapy.
Rifampin-induced thrombocytopenia has been recognized as an immunological reaction associated with intermittent high-dose therapy, and rarely seen with daily low-dose regimens. Our patient was a 33-year-old male with Marfan's syndrome who was given rifampin 600 mg/d po along with intravenous vancomycin for the treatment of Staphylococcus epidermidis endocarditis. His platelet count dropped from a baseline of 519,000/mm3 to 4000/mm3 after four doses of rifampin. Petechiae were present on the lower extremities without the presence of other bleeding sites. Rifampin, low-dose aspirin, and dipyridamole were discontinued. His platelet count returned to normal nine days after discontinuation of therapy. With the increasing use of rifampin for the treatment of nontuberculosis infections, clinicians should recognize the possibility of this drug causing such serious immunological reactions as thrombocytopenia, hemolytic anemia, acute renal failure, and shock with daily or intermittent therapy.
Pau
A K
AK
School of Pharmacy, West Virginia University Medical Center, Morgantow 26506.
Fisher
M A
MA
D000328:Adult; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D006801:Humans; D008297:Male; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced*
D012293:Rifampin